Moat.
Speed.
Allocation.
The platform moat that survives 2028 is being chosen this year.
This briefing tells you which platform moats survive 2028 in life sciences as AI rewrites build economics. Read it before your R&D allocation locks for the decade.
The 10-page briefing. Worth 20 minutes.
One email. One PDF. Worth twenty minutes of your week.
We send it once. Work emails only.
Monday 9:30, R&D platform review. Platform uptime green. Last quarter's Part 11 audit observations closed. IND filing for your lead programme going to the agency Friday. Phone buzzes. Your principal bioinformatician asking for coffee. A recruiter call from Genesis Therapeutics over the weekend. Your CSO forwards a press release: Recursion filed an IND in your core therapeutic area using AI-assisted target identification. Your CFO pinged this morning: "Board wants a three-year digital R&D envelope ahead of July, worth discussing."
You are not running one digital-R&D platform. You are running two, and only one is on your validation master plan. One runs today's regulated systems. The other has to exist by 2028: the longitudinal clinical corpus queryable across your historical trial book, the regulatory-submission platform that drafts modules your writers can defend, the CMC data layer that turns a decade of process development into a training corpus.
The moat that matters in 2028 is not above the model layer. It is underneath it, and in life sciences the layer underneath is data under GxP.
This is the question your CEO is already asking. The briefing below is what you want in your hand before the next R&D leadership review.
Build Velocity. Product Defensibility. R&D Capital Allocation.
Three questions every life-sciences CTO is tracking. The third is the crux. The first two are how you earn the right to answer it.
Is our platform shipping output that passes the next audit, or speed that fails inspection?
Bioinformatics and regulatory-writing teams are faster. Audit trails have agent-generated entries nobody mapped to a validation protocol. An AI-assistant that compresses literature review tenfold is a Part 11 finding waiting for inspection. Buy the regulated-AI substrate. Own the discipline that makes it pass.
What does our platform do that a Recursion at a fraction of our unit economics cannot copy?
Your feature edge commoditises every eighteen months when the next foundation model rolls. Your longitudinal clinical corpus, regulatory interaction history, and CMC process knowledge compound. Your principal bioinformatician carries reasoning never written down, and two recruiter calls landed this month.
Is our digital-R&D budget one instrument or two?
One funds the validated stack at lower unit cost. The other builds the 2028 corpus moat. On one hurdle rate the first wins every quarter. On one scorecard the second does not exist. The CTO who walks in with one budget runs the same programme every peer is running.
What you get when you download
An 11-page report for CTOs, CPOs, and Heads of Digital R&D at mid-market European life sciences firms. Designed to be read in one sitting before your next R&D leadership review.
Your industry, your digital R&D function, and why they are one problem
What is happening to mid-market life sciences: AI-native drug-discovery and clinical-trial platforms at a fraction of your per-asset unit economics, the feature layer commoditising every eighteen months, and competing INDs filed in your therapeutic area. What is happening inside your digital R&D platform: AI-assisted work shipping faster, audit-trail gaps, and the board AI-strategy ownership list your seat is not on. And the intersection: same force, two altitudes, one problem.
Four moves across build engine, platform and data, product thesis, and R&D bench
Absorb agent-generated velocity without a validation observation: validation wrappers on every agent-in-workflow, Part 11 controls on model-assisted audit trail. Build the corpus underneath the model layer through longitudinal clinical data, regulatory interaction history, and integration depth across LIMS, ELN, CDMS, eCTD. Stand AI-assisted submission on one protected programme. Keep the seniors, rebuild the junior pathway around composite pairing.
Five questions for your next R&D leadership review
Is your digital R&D budget one instrument or two, and what is the kill criterion on each? Name the AI-native in your therapeutic area. How many months to reconstruct translational reasoning if your principal bioinformatician leaves for Recursion? Where did the freed hours from AI-assisted work go, and is every output mapped to a validation protocol? Is your Q1 boundary agreement with the CEO and CSO written?
Calibrated for each seat at the table.